prostate cancer

FDA
Biotech

FDA flags concerns for AZ's camizestrant, Truqap ahead of adcomm

The FDA has taken issue with camizestrant's trial design and questions the Truqap data's clinical meaningfulness.
Angus Liu Apr 28, 2026 2:47pm
accelerated

Oric chases Pfizer into phase 3 hailing prostate cancer edge

Apr 1, 2026 9:53am
FDA conference hall

FDA to end 9-month adcomm hiatus with review of AZ cancer drugs

Mar 6, 2026 11:16am
weigh scale goliath outweigh balance bigger smaller even

BioNTech’s B7-H3 ADC hits ph. 3 at half the size of Merck’s

Feb 27, 2026 10:31pm
Metallic arrow symbols which are illuminated by blue and magenta lights merge on blue and magenta b

Astellas says 'I do' to Vir's T-cell engager in $1.7B deal

Feb 23, 2026 5:00pm
candle candles

Candel glows with $100M RTW deal to fund cancer drug launch

Feb 20, 2026 4:04am